Brexit Could Rob Industry Of Access To Markets Covered By 35 EU Free Trade Deals
Executive Summary
A coalition of life sciences industry bodies has written a position paper outlining its concerns about Brexit in areas such as EU free trade deals, customs declarations and tariff barriers.
You may also be interested in...
Pharma Execs Flag Up More Brexit Regulatory Woes – And A Possible Solution
Pharma executives painted a rather bleak picture of a UK regulatory system cast adrift by a hard Brexit, with problems likely in areas such as drug approvals, clinical trials and the role of the MHRA. One solution was proposed, however, to avoid the need for a free-standing UK approvals system for new drugs.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.